Q4 & FY22 Highlights

Non-COVID, COVID & Allied Revenue Rs. Cr. Total 431 607 498 497 486 386 438 420 374 386 105 74 43 41 37 49 49 68 4 10 2 8 7 10 Q4 FY21 Q1 FY22 Q2 FY22 Non COVID ■COVID* ■COVID Allied 1** Q3 FY22 ■COVID Allied 2*** Q4 FY22 *COVID includes RTPCR and Antibody tests; **COVID Allied 1 includes IL-6 & D-Dimer; ***COVID Allied 2 includes CRP, Ferritin & LDH Total Covid and Covid allied contribution at 14% in Q4 FY22, 13% in Q4 FY21 Note: Revenue in Q4 22 includes Rs 46 Cr (Non Covid 29.4 Cr, Covid Rs 16.6 Cr) and Q3 22 includes Rs. 49.1 Cr (Non Covid 24.6 Cr, Covid Rs 24.5 Cr) of Suburban wef 12th Nov 21. On transition from IGAAP to IND AS, revenue adjusted as per IND AS 115. 27 Dr Lal PathLabs

View entire presentation